Stockscreener 앱 받기
102.38
1.30%
0.91
Nuvalent Inc 주식(NUVL)의 최신 뉴스
Nuvalent CFO Balcom sells $1.13m in company stock - Investing.com
Nuvalent (NUVL) CFO sells 11,430 shares, exercises options under plan - Stock Titan
Insider Selling: Nuvalent (NASDAQ:NUVL) Insider Sells 5,500 Shares of Stock - MarketBeat
Nuvalent Insider Sold Shares Worth $547,524, According to a Recent SEC Filing - marketscreener.com
Nuvalent Insider Sold Shares Worth $545,691, According to a Recent SEC Filing - marketscreener.com
Nuvalent (NUVL) CLO sells shares, exercises options in 10b5-1 plan - Stock Titan
Nuvalent (NUVL) CDO nets 5,500-share sale after option exercise - Stock Titan
Nuvalent (NUVL) Submits NDA to FDA for Neladalkib in ALK-Positive NSCLC - Yahoo Finance
NUVL (NASDAQ) Form 144: Affiliate to sell 16,500 shares via option exercise - Stock Titan
Nuvalent: A Precision Oncology Platform With Two Near-Term Shots On Goal (NASDAQ:NUVL) - Seeking Alpha
Guardant Health Announces Multi-Year Strategic Collaboration with Nuvalent to Develop Companion Diagnostics and Support Potential Commercialization of Targeted Cancer Therapies Using the Guardant Infinity™ Platform - BioSpace
Guardant Health partners with Nuvalent on diagnostic tests By Investing.com - Investing.com South Africa
Guardant Health partners with Nuvalent on diagnostic tests - Investing.com
Guardant Health Inc. announces a multi-year strategic partnership with biopharmaceutical company Nuvalent - Bitget
CCORF Maintains Nuvalent(NUVL.US) With Buy Rating, Maintains Target Price $126 - Moomoo
Pictet Asset Management Holding SA Has $35.78 Million Holdings in Nuvalent, Inc. $NUVL - MarketBeat
Nuvalent (NUVL) Projected to Post Earnings on Thursday - MarketBeat
Universal Beteiligungs und Servicegesellschaft mbH Has $4.70 Million Position in Nuvalent, Inc. $NUVL - MarketBeat
[ARS] Nuvalent, Inc. SEC Filing - Stock Titan
[DEF 14A] Nuvalent, Inc. Definitive Proxy Statement - Stock Titan
Does Nuvalent (NUVL) have the potential to rally 37.26% as Wall Street analysts expect? - MSN
Nuvalent, Inc. (NUVL) Stock Analysis: Exploring a Promising 36% Upside with Strong Buy Ratings - DirectorsTalk Interviews
Leerink Partners Maintains Nuvalent (NUVL) Outperform Recommendation - MSN
Canaccord Genuity Remains a Buy on Nuvalent (NUVL) - The Globe and Mail
Assessing Nuvalent (NUVL) Valuation After FDA Review Progress And New ALK ROS1 Trial Data - Yahoo Finance
NUVL (Nuvalent Inc.) reports wider-than-expected Q4 2025 loss, shares edge 0.26% lower in post-earnings trading.Competitive Risk - Xã Thanh Hà
Trading the Move, Not the Narrative: (NUVL) Edition - Stock Traders Daily
Nuvalent stock presents AACR data ahead of September PDUFA By Investing.com - Investing.com Australia
Nuvalent stock presents AACR data ahead of September PDUFA - Investing.com
NUVL Reiterated by HC Wainwright & Co. -- Price Target Maintained at $155 - GuruFocus
Nuvalent to Present Pivotal Data from ALKOVE-1 Trial of Neladalkib in TKI Pre-treated Advanced ALK-positive NSCLC at the 2026 American Society of Clinical Oncology Annual Meeting - The Malaysian Reserve
HC Wainwright Reaffirms Buy Rating for Nuvalent (NASDAQ:NUVL) - MarketBeat
Nuvalent, Inc. (NUVL) Stock Analysis: Unveiling a 32% Potential Upside in Biotech Innovation - DirectorsTalk Interviews
Nuvalent data show activity of ROS1 inhibitor after next-gen TKIs - The Pharma Letter
Benjamin Lane Net Worth (2026) - GuruFocus
New Clinical and Preclinical Data for Investigational Candidate Zidesamtinib Presented at AACR Annual Meeting 2026 - Sahm
Nuvalent presents zidesamtinib data in pre-treated lung cancer By Investing.com - Investing.com Australia
Nuvalent presents zidesamtinib data in pre-treated lung cancer - Investing.com
Nuvalent, IncNuvalent Anticipates U.S. Commercial Launch Of Zidesamtinib In 2026 - TradingView
Nuvalent (NUVL) Stock Industry Rotation (Slow Drop) 2026-04-16Institutional Grade Picks - UBND thành phố Hải Phòng
Does FDA Filing For Neladalkib’s ALK-Targeted Lung Cancer Therapy Change The Bull Case For Nuvalent (NUVL)? - simplywall.st
Non-Small Cell Lung Cancer Clinical Trial Race Intensifies as 100+ Companies Competing in Therapeutic Segment Worldwide | DelveInsight - GlobeNewswire Inc.
Nuvalent (NUVL) CSO Pelish sells $323k in shares By Investing.com - Investing.com Australia
0.78%
3.01%
자본화:
|
볼륨(24시간):